Liu et al., "Direct control of hepatic glucose production by interleukin-13
in mice," The Journal of Clinical Investigation, vol.
induces dramatically different transcriptional programs in three human airway cell types.
Identification of four novel interleukin-13
Ongoing therapeutic trials for systemic agents in children and adolescents include the testing of biologic agents--such as dupilumab, interleukin-4 and interleukin-13
blockers, and JAK inhibitors--that target cytokine pathways important in AD.
Temann et al., "Interleukin-13
mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and interleukin-9," American Journal of Respiratory Cell and Molecular Biology, vol.
Pelletier et al., "Inhibition of tumor necrosis factor alpha-induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13
in osteoarthritic synovial fibroblasts: distinct targeting in the signaling pathways," Arthritis & Rheumatology, vol.
Natural killer cells decreased airway inflammation by encouraging programmed cell death in immune cells called eosinophils, whereas type 2 innate lymphoid cells promoted airway inflammation by secreting cell-signaling molecules called interleukin-13
receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis.
(Seattle, WA; 206-442-6744) announced that it has entered into a license agreement with Wyeth (Madison, NJ) for two United States Patent Applications for Interleukin-13
receptor subunit (IL-13R alpha2).
The product is a fully-human monoclonal antibody that blocks the signalling of interleukin-4 (IL-4) and interleukin-13
(IL-13), the proteins that play a significant role in type 2 inflammation.
Dupixent is a fully-human monoclonal antibody that inhibits the signalling of interleukin-4 (and interleukin-13
, two proteins that play a central role in type 2 inflammation.
Dupixent, which can be used with or without topical corticosteroids, is a targeted biologic therapy that inhibits signaling of interleukin-4 (IL-4) and interleukin-13
(IL-13), two key proteins that may play a central role in type 2 inflammation that underlies atopic dermatitis and several other allergic diseases added the companies.